Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment

References

• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.28264816
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis. 2003;62:611–616. doi:10.1136/ard.62.7.61112810421
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903–911. doi:10.1016/S0140-6736(01)06075-511567728
   PubMed Web of Science ®Google Scholar
• Waimann C, Marengo M, Achaval de S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis. Consequences of low adherence. Arthritis Rheum. 2013;65(6):1421–1429. doi:10.1002/art.3791723728826
   PubMed Web of Science ®Google Scholar
• van den Bemt BJF, van den Hoogen FH, Benraad B, Hekster Y, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36(10). doi:10.3899/jrheum.080430
   Web of Science ®Google Scholar
• Pasma A, den Boer E, van Spijker A, et al. Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. Rheumatology(Oxford). 2016;55(10):1812–1819. doi:10.1093/rheumatology/kew24727354686
   PubMed Web of Science ®Google Scholar
• Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–344.20016797
   PubMed Web of Science ®Google Scholar
• Stacey D, Légaré F, Col N, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;(1):CD001431.
   Web of Science ®Google Scholar
• Mühlbacher A, Johnson F. Choice experiments to quantify preferences for health and healthcare: state of the practice. Appl Heal Econ Heal Policy. 2016;14(3):253–266. doi:10.1007/s40258-016-0232-7
   PubMed Web of Science ®Google Scholar
• Nolla JM, Rodríguez M, Martin-Mola E, et al. Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adherence. 2016;10:1101–1113. doi:10.2147/PPA.S10631127382258
   PubMed Web of Science ®Google Scholar
• Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework.PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.008063324312488
   PubMed Web of Science ®Google Scholar
• Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abus Treat. 2016;66:48–53. doi:10.1016/j.jsat.2016.02.009
   PubMed Web of Science ®Google Scholar
• Chapman S, Dale P, Svedsater H, et al. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. NPJ Prim Care Respir Med. 2017;27(61). doi:10.1038/s41533-017-0061-7.
   Web of Science ®Google Scholar
• Alten R, Krüger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217–2228. doi:10.2147/PPA.S11777427843301
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349. doi:10.1016/j.jclinepi.2007.11.00818313558
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Heal. 2011;4:403–413. doi:10.1016/j.jval.2010.11.013
   Web of Science ®Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Heal. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Mathijssen EG, van Heuckelum M, van Dijk L, et al. A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. Patient Prefer Adherence. 2018;12:1537–1555. doi:10.2147/PPA.S17072130197505
   PubMed Web of Science ®Google Scholar
• Zwikker HE, van Dulmen S, van den Bemt BJ, van den Ende C. Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:1635–1645. doi:10.2147/PPA.S6684925525340
   PubMed Web of Science ®Google Scholar
• Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008;64(1):47–54. doi:10.1016/j.jpsychores.2007.07.01618157999
   PubMed Web of Science ®Google Scholar
• Orme B. Sample size issues for conjoint analysis In: Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research. Madison: Research Publishers LLC; 2010:57–66.
   Google Scholar
• Kongsted A, Nielsen A. Latent class analysis in health research. J Physiother. 2017;63(1):55–58. doi:10.1016/j.jphys.2016.05.01827914733
   PubMedGoogle Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Heal. 2016;4:300–315. doi:10.1016/j.jval.2016.04.004
   Web of Science ®Google Scholar
• Fraenkel L, Nowell WB, Michel G, Wiedmeyer C. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Ann Rheum Dis. 2018;77(5):678–683. doi:10.1136/annrheumdis-2017-21240729247126
   PubMed Web of Science ®Google Scholar
• Husni ME, Betts KA, Griffith J, Song Y, Ganguli A. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. Rheumatol Int. 2017;37(9):1423–1434. doi:10.1007/s00296-017-3760-z28623526
   PubMed Web of Science ®Google Scholar
• Poulos C, Hauber AB, González JM, Turpcu A. Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res. 2014;66(7):1008–1015. doi:10.1002/acr.22265
   Web of Science ®Google Scholar
• Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology(Oxford). 2010;49(2):289–294. doi:10.1093/rheumatology/kep35419920093
   PubMed Web of Science ®Google Scholar
• Louder AM, Singh A, Saverno K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Heal Drug Benefits. 2016;9(2):84–93.
   PubMed Web of Science ®Google Scholar
• Huynh TK, Østergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–99. doi:10.2147/PPA.S5515624470758
   PubMed Web of Science ®Google Scholar
• Hazlewood G, Bombardier C, Tomlinson G, et al. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology(Oxford). 2016;55(11):1959–1968. doi:10.1093/rheumatology/kew28027477807
   PubMed Web of Science ®Google Scholar
• Augustovski F, Beratarrechea A, Irazola V, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Heal. 2013;16(2):385–393. doi:10.1016/j.jval.2012.11.007
   Web of Science ®Google Scholar
• Horne R, Parham R, Driscoll R, Robinson A. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(6):837–844. doi:10.1002/ibd.2084619107771
   PubMed Web of Science ®Google Scholar
• Salampessy BH, Veldwijk J, Schuit AJ, de Wit GA, Lambooij MS. The predictive value of discrete choice experiments in public health: an exploratory application. Patient. 2015;8(6):521–529. doi:10.1007/s40271-015-0115-225618790
   PubMedGoogle Scholar